Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Sarcoma 2Osteosarcoma 2Neoplasms, Plasma Cell 2Multiple Myeloma 2Prostatic Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Cyclophosphamide 77Dexamethasone 74Melphalan 65Lenalidomide 50Bortezomib 50Peripheral Blood Stem Cell Transplantation 49fludarabine phosphate 47Busulfan 46Filgrastim 39Tacrolimus 37Antilymphocyte Serum 33Radiotherapy 30Mycophenolic Acid 30Thalidomide 28fludarabine 24Methotrexate 22Whole-Body Irradiation 21Cyclosporine 21Calcium Dobesilate 21Granulocyte Colony-Stimulating Factor 18Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 14daratumumab 11Prednisone 11Carmustine 11sargramostim 10Stem Cell Transplantation 10Sirolimus 10Rituximab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Plasma Cell × samarium Sm-153 lexidronam × Clear all
NCT00602706 2011-05-16

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Mayo Clinic

Phase 1/2 Completed
76 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00478075 2011-05-11

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡